Discusses Richard Rumelt's "strategy kernel" framework, emphasizing its critical application within the pharmaceutical industry. This framework, composed of diagnosis, guiding policy, and coherent actions, is presented as essential for navigating the complex challenges of pipeline assessment and early commercialization. The text highlights how a clear diagnosis of challenges, followed by a focused guiding policy and mutually reinforcing actions, can prevent common strategic missteps in pharma. Ultimately, the sources advocate for cross-functional integration across R&D, regulatory, and commercial teams to ensure strategic alignment and successful outcomes in drug development and market launch.